معرفی
David S. Rickman is an Associate Professor in the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College, where he has been affiliated since 2021. He holds a Ph.D. from Mount Sinai School of Medicine (1997) and a B.S. from Baylor University (1989).
His research focuses on molecular oncology, with expertise in prostate cancer mechanisms, including epigenetic reprogramming (EZH2, N-Myc), therapy resistance, neuroendocrine differentiation, and biomarker discovery. He employs advanced techniques like single-cell genomics, organoid modeling, and kinome profiling to identify therapeutic vulnerabilities.
Dr. Rickman leads multiple NIH-funded projects:
- Principal Investigator: 'DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer' (NCI, 2023–2028)
- Co-Principal Investigator: 'The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer' (NCI, 2025–2030)
- Principal Investigator (subaward): 'NOTCH signaling controls transformation to androgen-independent neuroendocrine prostate cancer' (NCI, 2019–2025)
- Co-Investigator: 'Development and optimization of CEACAM5-targeted alpha emitters' (Prostate Cancer Foundation, 2025–2027)
His recent publications (2019–2025) emphasize prostate cancer biology, epigenetic regulation, and therapeutic targeting, with recurrent themes of lineage plasticity, resistance mechanisms, and biomarker discovery.
